JP2014526447A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526447A5
JP2014526447A5 JP2014528879A JP2014528879A JP2014526447A5 JP 2014526447 A5 JP2014526447 A5 JP 2014526447A5 JP 2014528879 A JP2014528879 A JP 2014528879A JP 2014528879 A JP2014528879 A JP 2014528879A JP 2014526447 A5 JP2014526447 A5 JP 2014526447A5
Authority
JP
Japan
Prior art keywords
nasal
nose
carrier material
powder
inhaled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014528879A
Other languages
English (en)
Japanese (ja)
Other versions
JP6060163B2 (ja
JP2014526447A (ja
Filing date
Publication date
Priority claimed from DE102011112978A external-priority patent/DE102011112978A1/de
Application filed filed Critical
Publication of JP2014526447A publication Critical patent/JP2014526447A/ja
Publication of JP2014526447A5 publication Critical patent/JP2014526447A5/ja
Application granted granted Critical
Publication of JP6060163B2 publication Critical patent/JP6060163B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014528879A 2011-09-09 2012-08-13 キナーゼインヒビターとしてのベンゾニトリル誘導体 Expired - Fee Related JP6060163B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011112978A DE102011112978A1 (de) 2011-09-09 2011-09-09 Benzonitrilderivate
DE102011112978.6 2011-09-09
PCT/EP2012/003449 WO2013034238A1 (de) 2011-09-09 2012-08-13 Benzonitrilderivate als kinasehemmer

Publications (3)

Publication Number Publication Date
JP2014526447A JP2014526447A (ja) 2014-10-06
JP2014526447A5 true JP2014526447A5 (enExample) 2015-10-01
JP6060163B2 JP6060163B2 (ja) 2017-01-11

Family

ID=46679243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528879A Expired - Fee Related JP6060163B2 (ja) 2011-09-09 2012-08-13 キナーゼインヒビターとしてのベンゾニトリル誘導体

Country Status (27)

Country Link
US (1) US8969335B2 (enExample)
EP (1) EP2753615B1 (enExample)
JP (1) JP6060163B2 (enExample)
KR (1) KR101985984B1 (enExample)
CN (1) CN103930416B (enExample)
AR (1) AR087807A1 (enExample)
AU (1) AU2012306746B2 (enExample)
BR (1) BR112014005226A2 (enExample)
CA (1) CA2848148C (enExample)
DE (1) DE102011112978A1 (enExample)
DK (1) DK2753615T3 (enExample)
EA (1) EA025038B1 (enExample)
ES (1) ES2644128T3 (enExample)
HR (1) HRP20171296T1 (enExample)
HU (1) HUE036774T2 (enExample)
IL (1) IL231382A (enExample)
IN (1) IN2014KN00769A (enExample)
LT (1) LT2753615T (enExample)
MX (1) MX344335B (enExample)
NO (1) NO2753615T3 (enExample)
PL (1) PL2753615T3 (enExample)
PT (1) PT2753615T (enExample)
RS (1) RS56481B1 (enExample)
SG (1) SG2014015234A (enExample)
SI (1) SI2753615T1 (enExample)
WO (1) WO2013034238A1 (enExample)
ZA (1) ZA201402561B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014026176A2 (pt) * 2012-05-22 2017-06-27 Hoffmann La Roche dipiridilaminas substituídas e usos das mesmas
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
BR112015027381A8 (pt) 2013-05-01 2018-01-30 Hoffmann La Roche pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
CN104201295B (zh) * 2014-09-16 2017-05-03 深圳市华星光电技术有限公司 Oled的封装方法及oled结构
JP6499282B2 (ja) 2014-09-26 2019-04-10 ギリアード サイエンシーズ, インコーポレイテッド Tank結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体
US9994547B2 (en) 2014-10-06 2018-06-12 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of TBK1
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
CU20180059A7 (es) * 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
CN107286076A (zh) * 2016-04-05 2017-10-24 湖南华腾制药有限公司 一种哌啶类化合物的制备方法
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
CN107698491A (zh) * 2016-08-08 2018-02-16 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
CN107778216A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种氟取代哌啶衍生物的制备方法
CN107778215A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种氟取代哌啶衍生物的制备方法
CN108117510A (zh) * 2016-11-29 2018-06-05 湖南华腾制药有限公司 一种哌啶衍生物的制备方法
CN108610309A (zh) * 2016-12-13 2018-10-02 湖南华腾制药有限公司 一种哌啶衍生物的制备方法
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
KR20200071756A (ko) * 2017-10-17 2020-06-19 메르크 파텐트 게엠베하 피리미딘 TBK/IKKε 억제제 화합물 및 이의 용도
CA3078579A1 (en) * 2017-10-17 2019-04-25 Merck Patent Gmbh Pyrimidine tbk/ikk.epsilon. inhibitor compounds and uses thereof
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
WO2020206588A1 (en) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
CN112209886A (zh) * 2020-11-09 2021-01-12 沈阳药科大学 2-(3-氰基-4-烷氧基)苯基嘧啶衍生物及其制备方法和用途
CN113024565B (zh) * 2021-03-31 2022-09-13 上海启甄环境科技有限公司 一种放射性同位素碳-14标记依鲁替尼及其合成方法
WO2024239282A1 (zh) * 2023-05-24 2024-11-28 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1546117A2 (en) 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
WO2007129044A1 (en) 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
US20080153822A1 (en) 2006-11-30 2008-06-26 Martin Augustin Methods of treating pain
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2009030890A1 (en) 2007-09-03 2009-03-12 University Court Of The University Of Dundee Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma
EP2200436B1 (en) * 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
GB0903759D0 (en) 2009-03-04 2009-04-15 Medical Res Council Compound
WO2010151747A1 (en) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimine compounds and methods of making and using same
BR112012008677A2 (pt) 2009-10-12 2018-03-20 Myrexis Inc compostos amino-pirimidina como inibidores de tbkl e/ou ikk epsilon
GB201012105D0 (en) 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
CN103298794A (zh) * 2010-11-09 2013-09-11 塞尔卓姆有限公司 作为tyk2抑制剂的吡啶化合物及其氮杂类似物
EP2696683A4 (en) * 2011-04-12 2014-08-13 Alzheimer S Inst Of America Inc COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF IKK-MEDIATED KINASE EPSILON AND TANK BINDING KINASE-1 HEMMER

Similar Documents

Publication Publication Date Title
JP2014526447A5 (enExample)
JP2013544781A5 (enExample)
JP2014509313A5 (enExample)
JP2013534227A5 (enExample)
JP2015505541A5 (enExample)
JP2013541565A5 (enExample)
Weber et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art
Doktorovova et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation
Yang et al. Pulmonary drug delivery by powder aerosols
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
WO2014074797A8 (en) Ultra low density pulmonary powders
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
IN2014DN09377A (enExample)
AR098640A1 (es) Inhalador de polvo seco
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
EA201401354A1 (ru) Новая дозированная форма и препарат, содержащий абедитерол
EP4233874A3 (en) Acetylsalicylic acid for reducing the risk of a thromboembolic event
EA201590734A8 (ru) Вдыхаемые лекарственные средства
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
JP2004534813A5 (enExample)
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
JP2014062109A5 (enExample)
HK1215167A1 (zh) 可吸入药用组合物和含有该药用组合物的吸入器装置
RU2016103313A (ru) Липидная наночастица с полимиксином